Form 4 for DXCM Dexcom
Accepted 2022-11-22 00:00:00 ET · period of report 2022-11-21 · accession 0001093557-22-000177 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-11-22 | 2022-11-21 | DXCM | Stern Sadie | EVP Chief Human Resources Offi | D - Sale to Iss | $112.62 | -3,844 | 68.4K | -5% | -$432.9K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-11-21 | D | D | 3,844 | $112.62 | 68,384 | D | — | — | (F1) Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. (F2) Included in this number are 59,312 unvested restricted stock units, 21,188 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 6,684 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 15,024 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,416 of which were granted on November 19, 2020 and shall vest through November 19, 2024. |